“The Substance Abuse and Mental Health Services Administration (SAMHSA), as part of the US Department of Health and Human Services (HHS), has issued new reporting requirements for physicians who will be authorized to prescribe the opioid use disorder treatment medication buprenorphine at the new limit of 275 patients. The requirements, published on September 27, 2016 in the Federal Register, are a key step in increasing access to medication-assisted treatment for opioid-related disorders.
Under the new rule, physicians prescribing buprenorphine at the maximum patient cap of 275 will be required to complete a SAMHSA reporting form each year. This reporting will help SAMHSA ensure that physicians prescribing at the new higher levels are in compliance with safe and appropriate prescribing practices. Practitioners will be required to report the annual caseload of patients by month, the number of patients provided behavioral health services and referred to behavioral health services, and features of the practitioner’s diversion control plan.
Read more at: http://www.samhsa.gov/newsroom/press-announcements/201609271100
Source: The Substance Abuse Mental Health Services Administration – September 27, 2016